Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2016 | Research article

Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model

Authors: Hye-Youn Kim, Jinhee Kim, Huyen Trang Ha Thi, Ok-Sun Bang, Won-Suk Lee, Suntaek Hong

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Abstract

Background

KIOM-CRC#BP3B (BP3B) is a novel herbal prescription that is composed of three plant extracts. Our preliminary study identified that BP3B exhibited potent anti-proliferative activity against various types of cancer cell lines in vitro. Because the in vivo anti-tumor effect of BP3B is not evaluated before clinical trial, we want to test it using patient’s samples.

Methods

To confirm the in vivo anti-cancer effect of BP3B, we used genetically characterized patient-derived colon tumor xenograft (PDTX) mouse model. Anti-cancer activity was evaluated with apoptosis, proliferation, angiogenesis and histological analysis.

Results

Oral administration of BP3B significantly inhibited the tumor growth in two PDTX models. Furthermore, TUNEL assay showed that BP3B induced apoptosis of tumor tissues, which was associated with degradation of PARP and Caspase 8 and activation of Caspase 3. We also observed that BP3B inhibited cancer cell proliferation by down-regulation of Cyclin D1 and induction of p27 proteins. Inhibition of angiogenesis in BP3B-treated group was observed with immunofluorescence staining using CD31 and Tie-2 antibodies.

Conclusion

These findings indicated that BP3B has a strong growth-inhibitory activity against colon cancer in in vivo model and will be a good therapeutic candidate for treatment of refractory colon cancer.

Available only for authorised users

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–99.CrossRefPubMed

Buyse M, Thirion P, Carlson R, Burzykowski T, Molenberghs G, Piedbois P. Tumour response to first line chemotherapy improves the survival of patients with advanced colorectal cancer. Lancet. 2000;356:373–8.CrossRefPubMed

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.CrossRefPubMed

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.CrossRefPubMed

Knight R, Miller L, Pirotta N, Elfring G, Locker P, Saltz L. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol. 2000;19:991a.

de Gramont AD, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.PubMed

Young A, Rea D. ABC of colorectal cancer: treatment of advanced disease. BMJ. 2000;321:1278–81.CrossRefPubMedPubMedCentral

Iacovelli R, Pietrantonio F, Maggi C, de Braud F, Di Bartolomeo M. Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. Crit Rev Oncol Hematol. 2015;S1040:30043.

Saito RF, Tortelli TC, Jacomassi MD, Otake AH, Chammas R. Emerging targets for combination therapy in melanomas. FEBS Lett. 2015;589:3438–48.CrossRef

10.

Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, Furuya T, Nishimura T, Sakata K, Yoshimatsu K, Takenouchi H, Tsunedomi R, Inoue Y, Kanekiyo S, Shindo Y, Suzuki N, Yoshino S, Shinozaki H, Kamiya A, Furukawa H, Yamanaka T, Fujita T, Kawakami Y, Oka M. A phase IotaI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014;12:108.CrossRefPubMedPubMedCentral

11.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:359–65.CrossRefPubMedPubMedCentral

12.

Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2:45ra59.CrossRefPubMed

13.

Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66:3351–4.CrossRefPubMed

14.

Boedigheimer MJ, Freeman DJ, Kiaei P, Damore MA, Radinsky R. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. Neoplasia. 2013;15:125–32.CrossRefPubMedPubMedCentral

15.

Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73.CrossRefPubMedPubMedCentral

16.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2009;13:3989–98.CrossRef

17.

Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Euro J Cancer. 2004;40:802–20.CrossRef

18.

Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12:473–80.CrossRefPubMed

19.

Lee YJ, Kim NS, Kim H, Yi JM, Oh SM, Bang OS, Lee J. Cytotoxic and anti-inflammatory constituents from the seeds of Descurainia sophia. Arch Pharm Res. 2013;36:536–41.CrossRefPubMed

20.

Khan M, Xiao Y, Yu B, Wang N, Rasul A, Yi F, Yang L, Yang H, Ma T. Artabotryside A, a constituent from Descurainia sophia (L.) induces cell death in U87 glioma cells through apoptosis and cell cycle arrest at G2/M phase. J Med Plants Res. 2012;6:3754–65.

21.

Sun K, Li X, Li W, Wang J, Liu J, Sha Y. Two new lactones and one new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one from Descurainia sophia. Chem Pharm Bull. 2004;52:1483–6.CrossRefPubMed

22.

Lee J, Lee YJ, Kim J, Bang OS. Pyranocoumarins from root extracts of Peucedanum praeruptorum Dunn with multidrug resistance reversal and anti-inflammatory activities. Molecules. 2015;20:20967–78.CrossRefPubMed

23.

Uto T, Tung NH, Appiah-Opong R, Aning A, Morinaga O, Edoh D, Nyarko K, Shoyama Y. Antiproliferative and pro-apoptotic activity of diarylheptanoids isolated from the bark of alnus japonica in human leukemia cell lines. Am J Chin Med. 2015;43:757–67.CrossRefPubMed

24.

Kang S, Kim JE, Li Y, Jung SK, Song NR, Thimmegowda NR, Kim BY, Lee HJ, Bode AM, Dong Z, Lee KW. Hirsutenone in Alnus extract inhibits akt activity and suppresses prostate cancer cell proliferation. Mol Carcinog. 2015;54:1354–62.CrossRefPubMed

25.

Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;340:1120–4.CrossRefPubMed

26.

Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. International journal of cancer. Int J Cancer. 1993;55:371–4.CrossRefPubMed

27.

Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Nat Cancer Inst. 1992;84:1875–87.CrossRefPubMed

28.

Khodarahmi E, Asghari GH, Hassanzadeh F, Mirian M, Khodarahmi GA. Cytotoxic evaluation of volatile oil from Descurainia sophia seeds on MCF-7 and HeLa cell lines. Res Pharm Sci. 2015;10:169–76.PubMedPubMedCentral

29.

Yu PJ, Jin H, Zhang JY, Wang GF, Li JR, Zhu ZG, Tian YX, Wu SY, Xu W, Zhang JJ, Wu SG. Pyranocoumarins isolated from Peucedanum praeruptorum Dunn suppress lipopolysaccharide-induced inflammatory response in murine macrophages through inhibition of NF-kappaB and STAT3 activation. Inflammation. 2012;35:967–77.CrossRefPubMed

30.

Liang T, Yue W, Li Q. Chemopreventive effects of Peucedanum praeruptorum DUNN and its major constituents on SGC7901 gastric cancer cells. Molecules. 2010;15:8060–71.CrossRefPubMed

31.

Yang L, Li XB, Yang Q, Zhang K, Zhang N, Guo YY, Feng B, Zhao MG, Wu YM. The neuroprotective effect of praeruptorin C against NMDA-induced apoptosis through down-regulating of GluN2B-containing NMDA receptors. Toxicol In Vitro. 2013;27:908–14.CrossRefPubMed

32.

Sung SH, Lee M. Anti-adipogenic activity of a new cyclic diarylheptanoid isolated from Alnus japonica on 3 T3-L1 cells via modulation of PPARgamma, C/EBPalpha and SREBP1c signaling. Bioorg Med Chem Lett. 2015;25:4648–51.CrossRefPubMed

33.

Tung NH, Suzuki M, Uto T, Morinaga O, Kwofie KD, Ammah N, Koram KA, Aboagye F, Edoh D, Yamashita T, Yamaguchi Y, Setsu T, Yamaoka S, Ohta N, Shoyama Y. Anti-trypanosomal activity of diarylheptanoids isolated from the bark of Alnus japonica. Am J Chin Med. 2014;42:1245–60.CrossRefPubMed

34.

Gura T. Systems for identifying new drugs are often faulty. Science. 1997;278:1041–2.CrossRefPubMed

35.

Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012;14:574–83.CrossRefPubMedPubMedCentral

36.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012;14:R11.CrossRefPubMedPubMedCentral

37.

Gutmann DH, Maher EA, Van Dyke T. Mouse models of human cancers consortium workshop on nervous system tumors. Cancer Res. 2006;66:10–3.CrossRefPubMed

38.

Lee WS, Kim HY, Seok JY, Jang HH, Park YH, Kim SY, Shin DB, Hong S. Genomic profiling of patient-derived colon cancer xenograft models. Medicine. 2014;93:e298.CrossRefPubMedPubMedCentral

39.

Martinez-Garcia R, Juan D, Rausell A, Munoz M, Banos N, Menendez C, Lopez-Casas PP, Rico D, Valencia A, Hidalgo M. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 2014;6:27.CrossRefPubMedPubMedCentral

Title: Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model
Authors: Hye-Youn Kim
Jinhee Kim
Huyen Trang Ha Thi
Ok-Sun Bang
Won-Suk Lee
Suntaek Hong
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-016-1447-8

At a glance: The STEP trials

Springer Medicine

Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Acthaside: a new chromone derivative from Acacia ataxacantha and its biological activities

Flavonoids of Polygonum hydropiper L. attenuates lipopolysaccharide-induced inflammatory injury via suppressing phosphorylation in MAPKs pathways

Anti-inflammatory and burn injury wound healing properties of the shell of Haliotis diversicolor

Ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry analysis of the impact of processing on toxic components of Kansui Radix

Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro

Treatment with Rhodiola crenulata root extract ameliorates insulin resistance in fructose-fed rats by modulating sarcolemmal and intracellular fatty acid translocase/CD36 redistribution in skeletal muscle